PET study of changes in [11C]AZ14132516 uptake following administration of AZD7798 to healthy participants and patients with Crohn’s disease
Phase 1
Recruiting
- Conditions
- Crohn's DiseaseTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2023-505471-78-00
- Lead Sponsor
- Astrazeneca AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular target does AZD7798 modulate to alter [11C]AZ14132516 radioligand uptake in Crohn’s disease?
How does AZD7798’s mechanism compare to anti-TNF therapies like infliximab in early Crohn’s disease trials?
Which biomarkers correlate with [11C]AZ14132516 PET signal changes after AZD7798 administration in IBD?
What adverse events are reported in Phase I trials of AZD7798 for inflammatory bowel disease (IBD)?
Are there AstraZeneca compounds or combination strategies targeting similar pathways to AZD7798 for Crohn’s?